Research and Markets: DRG Insights: Benign Prostate Hyperplasia (G7)

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "DRG Insights: Benign Prostate Hyperplasia (G7)" to their offering.

DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives.

Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) affect 159 million men aged 40 or older in the major pharmaceutical markets we cover (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Demographic trends suggest an increase in the prevalent LUTS and BPH populations as a result of aging populations in the markets under study.

Therapies for LUTS and BPH are very effective, but opportunity remains for therapies that can increase patient adherence to medications. Also, BPH is a progressive disease, and new therapies are needed that can stop disease progression and prevent surgery.

Key Topics Covered:

Executive Summary

Current Market Landscape

Etiology & Pathophysiology

Staging/Patient Segmentation

Select Drug Targets

Growth Drivers & Constraints

Key Metrics

Population Dynamics

Market Landscape

Current Therapies

Treatment Algorithms

Country Specific Decision Trees

Comparison of Key Agents

Expert Insight on Prescribing Trends

Importance of Drug Attributes in Prescribing Decisions

Pricing & Reimbursement

Factors Influencing Pharmacy Director Tier Placement Decisions

Accessibility and Cost Hurdles

Reimbursement Environment

Unmet Needs Emerging Therapies

Near-term Outlook

Long-term Outlook

Important Endpoints in Prescribing Decisions


2010 and 2010 sales and Market Share

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets